Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US-based specialty pharmaceutical company EpiCept has amended its December 20, 2006 licensing agreement with Durect, granting Durect exclusive, worldwide rights to certain EpiCept intellectual property for a transdermal patch containing bupivacaine for the treatment of back pain.
Subscribe to our email newsletter
Under the terms of the amended agreement, EpiCept has granted Durect royalty-free, fully paid up, perpetual and irrevocable rights to the intellectual property licensed as part of the original agreement in exchange for a cash payment of $2.25 million from Durect.
EpiCept intends to use the proceeds of this non-dilutive cash payment as working capital and for general corporate purposes as the company prepares for the launch of Ceplene (histamine dihydrochloride) following receipt of final marketing authorization in Europe, which EpiCept anticipates receiving within the next several weeks.